With more than 30 years of experience in pharmaceutical R&D, Ted has been instrumental in the discovery and development of multiple marketed products. Since 2004 he has chaired the board of The Cystic Fibrosis Foundation Therapeutics, Inc. Ted currently serves as CSO of BioMotiv. Prior to that, Ted spent 12 years with Johnson & Johnson in high ranking managerial positions. Before Johnson & Johnson, Ted spent 17 years with SmithKline Beecham in various VP tier roles. He holds a B.S. degree in Pharmacy from the University of Wisconsin and a Ph.D. in Pharmacology and Toxicology from West Virginia University.

 the greatest challenge is the need to improve the productivity of R&D. In the future, traditional pharmaceuticals, either large or small molecules, may not be sufficient to satisfy unmet medical needs. Particularly with respect to life saving or life changing therapies, products that rely on convergent technologies will become increasingly important. Technology convergence involves combining two or more distinct disciplines or technologies to create a new solution for the prevention or treatment of diseases. This presentation will focus on examples of convergent technologies and their application to the treatment of disease.